Department of Gastroenterology and Hepatology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.
Department of Gastroenterology and Hepatology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.
Eur J Cancer. 2021 Sep;155:116-126. doi: 10.1016/j.ejca.2021.07.007. Epub 2021 Aug 7.
Considering the poor prognosis of oesophageal adenocarcinoma (EAC), it is important to identify individuals at increased risk of developing EAC who may benefit from early detection and prevention strategies. We aimed to determine whether individuals with a positive family history of Barrett's oesophagus (BE) and EAC are at an increased risk of oesophageal neoplasia.
In a multi-centre case-control study, BE patients with or without related oesophageal neoplasia and randomly selected population controls filled out a questionnaire to collect information on family history and other risk factors for BE and EAC. Positive family history was defined as having ≥1 first-degree relative with BE or EAC whose diagnosis was histologically confirmed in the Dutch nationwide histopathology database.
We included 480 BE patients and 420 controls without BE who had a total of 6393 first-degree relatives. A pathologically confirmed positive family history was significantly higher in BE patients compared with controls (6.5% versus 0.9; p < 0.001). Positive family history was independently associated with an increased risk of BE (OR 5.04; 95% CI 1.45-17.58; p = 0.01) after adjusting for known risk factors, such as gastroesophageal reflux disease and body mass index, and family size.
We found that familial clustering of BE and EAC is present in 6.5% of Dutch BE patients. Subjects with ≥1 first-degree relative with BE or EAC have a 5-fold increased risk of BE and EAC. These findings emphasize the importance of a detailed family history in patients with BE or EAC to identify individuals at increased risk who may benefit from early detection strategies to prevent EAC-related mortality.
考虑到食管腺癌(EAC)的预后较差,识别患有 Barrett 食管(BE)和 EAC 的家族史阳性的个体并对其进行早期检测和预防策略是非常重要的。我们旨在确定具有 BE 和 EAC 阳性家族史的个体是否患有食管肿瘤的风险增加。
在一项多中心病例对照研究中,BE 患者(伴或不伴相关食管肿瘤)和随机选择的人群对照者填写问卷,收集 BE 和 EAC 的家族史和其他危险因素信息。阳性家族史定义为≥1 位一级亲属患有 BE 或 EAC,其诊断在荷兰全国组织病理学数据库中经组织学证实。
我们纳入了 480 例 BE 患者和 420 例无 BE 的对照者,共 6393 位一级亲属。BE 患者的病理证实阳性家族史明显高于对照组(6.5%比 0.9%;p<0.001)。在调整了已知危险因素(如胃食管反流病和体重指数以及家庭规模)后,阳性家族史与 BE 风险增加独立相关(OR 5.04;95%CI 1.45-17.58;p=0.01)。
我们发现,荷兰 BE 患者中存在 6.5%的 BE 和 EAC 家族聚集。≥1 位一级亲属患有 BE 或 EAC 的个体患有 BE 和 EAC 的风险增加 5 倍。这些发现强调了在 BE 或 EAC 患者中详细询问家族史的重要性,以识别出具有较高风险的个体,从而可能受益于早期检测策略来预防与 EAC 相关的死亡率。